Immunomodulatory effect of selenosemicarbazides and selenium inorganic compounds, distribution in organs after selenium supplementation.
Antioxidant properties of selenium producing a protective barrier against free radicals play an important role in numerous metabolic and immunologic processes associated with oxidation-reduction reactions which take place during intracellular digestion of phagocyted bacteria. The aim of our study was to examine the properties of an organic compound of selenium, 4-(o-tolilo)-selenosemicarbazide of p-chlorobenzoic acid in terms of its retention in organs, effect on erythropoesis and phagocytic abilities of neutrophiles as well as antioxidant properties in neutrophiles tested with NBT test. This compound as well as inorganic sodium selenate was given to Swiss mice at the dose of 10(-3) g Se/kg for the period of 10 days. The concentrations of selenium in livers of mice treated with sodium selenate and selenosemicarbazide were found to be higher than in controls (18.7 micrograms lg-1 and 23.2 micrograms lg-1 vs. 12 micrograms lg-1, respectively). Analysis of blood cells count has shown a significant decrease in neutrophile levels in both groups treated with selenium. The influence of selenium compounds on phagocytosis and especially NBT test has been determined (3.8% of positive cells in the controls vs. 2.2% and 0.9% in the groups treated with sodium selenate and selenosemicarbazide, respectively). Our preliminary investigations suggest that selenosemicarbazides are biologically active compounds and can modify neutrophile functions.
Musik
I
I
Chemistry Deptartment, University Medical School, Lublin, Poland.
Koziol-Montewka
M
M
Toś-Luty
S
S
Pasternak
K
K
Latuszyńska
J
J
Tokarska
M
M
Kielczykowska
M
M
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D004920:Erythropoiesis / Q000187:drug effects*; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D051379:Mice; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology*; D016566:Organoselenium Compounds / Q000493:pharmacokinetics / Q000494:pharmacology*; D010084:Oxidation-Reduction; D010587:Phagocytosis / Q000187:drug effects; D064586:Selenic Acid; D018036:Selenium Compounds / Q000493:pharmacokinetics / Q000494:pharmacology*; D013154:Spleen / Q000378:metabolism; D014018:Tissue Distribution
C409891:4-chlorobenzoic acid 4-(2-tolyl)selenosemicarbazide; D000975:Antioxidants; D016566:Organoselenium Compounds; D018036:Selenium Compounds; D064586:Selenic Acid